Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Enterprise Value (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Enterprise Value over the past 16 years, most recently at -$8.3 million for Q2 2025.

  • For Q2 2025, Enterprise Value rose 2.33% year-over-year to -$8.3 million; the TTM value through May 2025 reached -$8.3 million, up 2.33%, while the annual FY2025 figure was -$8.3 million, 2.33% up from the prior year.
  • Enterprise Value for Q2 2025 was -$8.3 million at Lifecore Biomedical, Inc. \De\, down from -$5.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$609000.0 in Q4 2021 and troughed at -$19.1 million in Q2 2023.
  • A 5-year average of -$4.9 million and a median of -$2.7 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 75.4% in 2021 and later tumbled 1826.44% in 2023.
  • Year by year, Enterprise Value stood at -$609000.0 in 2021, then tumbled by 875.04% to -$5.9 million in 2022, then plummeted by 221.51% to -$19.1 million in 2023, then soared by 50.47% to -$9.5 million in 2024, then grew by 12.59% to -$8.3 million in 2025.
  • Business Quant data shows Enterprise Value for LFCR at -$8.3 million in Q2 2025, -$5.4 million in Q1 2025, and -$9.5 million in Q4 2024.